1.125
1.36%
0.025
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.10
Aprire:
$1.07
Volume 24 ore:
3.82M
Relative Volume:
1.48
Capitalizzazione di mercato:
$127.69M
Reddito:
$257.24M
Utile/perdita netta:
$-237.89M
Rapporto P/E:
-0.3389
EPS:
-3.32
Flusso di cassa netto:
$-175.17M
1 W Prestazione:
+44.32%
1M Prestazione:
+27.31%
6M Prestazione:
-46.39%
1 anno Prestazione:
-43.97%
Coherus Biosciences Inc Stock (CHRS) Company Profile
Nome
Coherus Biosciences Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Confronta CHRS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
CHRS | 1.129 | 127.69M | 257.24M | -237.89M | -175.17M | -3.32 |
VRTX | 449.14 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 748.83 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.39 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.01 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.99 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-07-24 | Iniziato | Citigroup | Buy |
2023-05-01 | Iniziato | Truist | Buy |
2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
2022-06-14 | Iniziato | UBS | Neutral |
2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
2020-07-16 | Iniziato | BofA Securities | Neutral |
2020-04-17 | Iniziato | SunTrust | Buy |
2019-08-13 | Iniziato | Mizuho | Buy |
2019-08-02 | Reiterato | H.C. Wainwright | Buy |
2019-08-02 | Reiterato | Maxim Group | Buy |
2019-06-11 | Iniziato | Barclays | Overweight |
2019-05-07 | Iniziato | H.C. Wainwright | Buy |
2018-08-28 | Iniziato | H.C. Wainwright | Buy |
2018-03-09 | Reiterato | Maxim Group | Buy |
2017-08-08 | Reiterato | JP Morgan | Overweight |
2017-06-13 | Reiterato | Maxim Group | Buy |
2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
2016-10-19 | Iniziato | Robert W. Baird | Outperform |
2016-09-07 | Iniziato | Maxim Group | Buy |
2016-07-27 | Iniziato | Citigroup | Buy |
2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Biosciences Inc Borsa (CHRS) Ultime notizie
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Growth in Short Interest - MarketBeat
Los Angeles Capital Management LLC Has $967,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - MarketBeat
Coherus stock rallies 19% on Q3 earnings, Udenyca production update - MSN
Robert W. Baird Has Lowered Expectations for Coherus BioSciences (NASDAQ:CHRS) Stock Price - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript - Insider Monkey
Coherus BioSciences' (CHRS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges - GuruFocus.com
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Coherus BioSciences Reports Strong Q3 2024 Growth - TipRanks
Coherus BioSciences earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Coherus BioSciences: Q3 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30% - Simply Wall St
Coherus BioSciences Q3 2024 Earnings Preview - MSN
CHRS stock touches 52-week low at $0.71 amid market challenges - Investing.com Australia
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to K - GuruFocus.com
Coherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Brokerages Set Coherus BioSciences, Inc. (NASDAQ:CHRS) Price Target at $7.13 - MarketBeat
CHRS stock plunges to 52-week low, hitting $0.79 By Investing.com - Investing.com Canada
CHRS stock plunges to 52-week low, hitting $0.79 - Investing.com India
Warning: CHRS is at high risk of performing badly - MSN
Such Is The Power Of Coherus Biosciences Inc (NASDAQ: CHRS) - Stocks Register
Exclusive-Russia to use ship-to-ship LNG loadings to free up ice-class tankers By Reuters - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Lowered to "Hold" at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.85 amid market challenges - Investing.com India
CHRS stock touches 52-week low at $0.85 amid market challenges By Investing.com - Investing.com South Africa
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Increase in Short Interest - MarketBeat
How should investors view Coherus Biosciences Inc (CHRS)? - US Post News
Coherus Biosciences Inc Inc. (CHRS) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
StockNews.com Upgrades Coherus BioSciences (NASDAQ:CHRS) to “Buy” - Defense World
Financial Metrics Unveiled: Coherus Biosciences Inc (CHRS)’s Key Ratios in the Spotlight - The Dwinnex
AQR Capital Management LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
719,999 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by AQR Capital Management LLC - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Biosciences Inc (CHRS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Coherus Biosciences Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):